This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 28/10/1723    most recent ATVBAHA.108.173344v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Devlin, C. M. Articles by Tabas, I. Search for Related Content PubMed PubMed Citation Articles by Devlin, C. M. Articles by Tabas, I. Related Collections Lipids Animal models of human disease Pathophysiology Cell biology/structural biology Genetically altered mice Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1723.)
© 2008 American Heart Association, Inc.

Integrative Physiology/Experimental Medicine

Acid Sphingomyelinase Promotes Lipoprotein Retention Within Early Atheromata and Accelerates Lesion Progression

Cecilia M. Devlin; Andrew R. Leventhal; George Kuriakose; Edward H. Schuchman; Kevin Jon Williams; Ira Tabas

From the Departments of Medicine (C.M.D., A.R.L., G.K., I.T.), Pathology & Cell Biology (I.T.), and Physiology & Cellular Biophysics (I.T.), Columbia University, New York; the Department of Genetics and Genomic Sciences (E.H.S.), Mount Sinai School of Medicine, New York; and the Division of Endocrinology, Diabetes, and Metabolic Diseases, Department of Medicine (K.J.W.), Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pa.

Correspondence to Ira Tabas, MD, PhD, Department of Medicine, Columbia University, 630 West 168th Street, New York, NY 10032. E-mail iat1{at}columbia.edu

Objective— The key initial step in atherogenesis is the subendothelial retention of apolipoprotein B–containing lipoproteins. Acid sphingomyelinase (acid SMase), an enzyme present extracellularly within the arterial wall, strongly enhances lipoprotein retention in model systems in vitro, and retained lipoproteins in human plaques are enriched in ceramide, a product of SMase. We now sought to test a direct causative role for acid SMase in lipoprotein retention and atherogenesis in vivo.

Methods and Results— We studied atherogenesis and lipoprotein retention in Asm^–/– versus Asm^+/+ mice on the Apoe^–/– and Ldlr^–/– backgrounds. Asm^–/–;Apoe^–/– mice had a 40% to 50% decrease in early foam cell aortic root lesion area compared with Asm^+/+;Apoe^–/– mice (P<0.05) despite no difference in plasma cholesterol or lipoproteins. To assay lipoprotein retention in vivo, the two groups of mice were injected with fluorescently labeled Apoe^–/– lipoproteins. Early foam cell lesions of Asm^–/–;Apoe^–/– mice showed a striking 87% reduction in lipoprotein trapping (P<0.0001) compared with Asm^+/+;Apoe^–/– lesions. Similar results were obtained with Ldlr^–/– mice, including an 81% reduction in lipoprotein retention within Asm^–/–;Ldlr^–/– lesions compared with Asm^+/+;Ldlr^–/– lesions (P<0.0005).

Conclusions— These findings support a causal role for acid SMase in lipoprotein retention and lesion progression and provides further support for the response-to-retention model of atherogenesis.

Key Words: atherosclerosis-pathophysiology • animal models of human disease • sphingomyelinase • lipoprotein retention

This article has been cited by other articles:

				C. Pavoine and F. Pecker Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology Cardiovasc Res, May 1, 2009; 82(2): 175 - 183. [Abstract] [Full Text] [PDF]